Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study-Reference-Cited by-同舟云学术

Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

Published:2022-01-29 Issue:10 Volume:126 Page:1394-1400
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Zaibet Sonia,Hautefeuille Vincent,Auclin Edouard,Lièvre Astrid,Tougeron David^ORCID,Sarabi Mathieu,Gilabert Marine,Wasselin Julie,Edeline Julien^ORCID,Artru Pascal,Bechade Dominique,Morin Clémence,Ducoulombier Agnes,Taieb Julien^ORCID,Pernot Simon^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-022-01713-w.pdf

Reference21 articles.

1. Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5:2649–56. https://doi.org/10.1002/cam4.767

2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud, Yves B, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl J Med. 2011;2011:1817–25.

3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine (MPACT Trial). N. Engl J Med. 2013;369:1691–703. https://doi.org/10.1056/NEJMoa1304369

4. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. JCO. 2014;32:2423–9. https://doi.org/10.1200/JCO.2013.53.6995

5. Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78–87. https://doi.org/10.1016/j.ejca.2018.12.007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Gemcitabine Plus Nab-paclitaxel in Second-line Treatment of Metastatic Pancreatic Cancer: a Multicenter Retrospective Study in Turkey;2024-09-10

2. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment;Cancer Medicine;2024-06

3. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma;Pancreatology;2024-05

4. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma;2023-11-02

5. Peak Risk of Recurrence Occurs during the First Two Years after a Pancreatectomy in Patients Receiving Neoadjuvant FOLFIRINOX;Cancers;2023-10-26